



## Clinical trial results:

### A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Men and Transgender Women Who Have Sex With Men, and Are at High Risk for HIV-1 Infection

#### Summary

EudraCT number	2020-003309-79
Trial protocol	FR Outside EU/EEA
Global end of trial date	04 August 2023

#### Results information

Result version number	v2 (current)
This version publication date	01 May 2025
First version publication date	14 February 2024
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	MK-8591-024
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04652700
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002938-PIP01-20
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 August 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 August 2023
Global end of trial reached?	Yes
Global end of trial date	04 August 2023
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the safety and tolerability of oral islatravir (ISL) once monthly (QM) as Preexposure Prophylaxis (PrEP) in cisgender men who have sex with men and transgender women who have sex with men and who are at high risk of HIV-1 infection with 48 or 96 weeks of treatment and a follow-up of  $\geq 42$  days.

Due to decreased lymphocyte and CD4+ T-cell counts across the ISL program, blinded dosing was halted on 10-Dec-2021, with no further enrollment. Thus, no participants <18 years of age were randomized. Assessments conducted prior to then are designated as Part 1. In Part 2, participants from Part 1 were switched to open-label PrEP therapy with emtricitabine/tenofovir disoproxil (FTC/TDF) or emtricitabine/tenofovir alafenamide (FTC/TAF) while continuing in the study. In Part 3, the study was unblinded to original randomized intervention group, and participants were permitted to continue receiving unblinded FTC/TDF or FTC/TAF until the end of the study.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 March 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 12
Country: Number of subjects enrolled	Japan: 26
Country: Number of subjects enrolled	South Africa: 59
Country: Number of subjects enrolled	Thailand: 68
Country: Number of subjects enrolled	United States: 277
Country: Number of subjects enrolled	Peru: 52
Worldwide total number of subjects	494
EEA total number of subjects	12

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	492
From 65 to 84 years	2
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Participants were randomized at 23 study sites in France, Japan, Peru, South Africa, and the United States.

### Period 1

Period 1 title	Part 1: Blinded Study Medication
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF

Arm description:

Participants received 60 mg tablet of ISL once monthly (QM) plus placebo to FTC/TDF tablet once daily (QD) or placebo to FTC/TAF tablet QD in Part 1. Participants then received open-label FTC/TDF or FTC/TAF in Parts 2 and 3.

Arm type	Experimental
Investigational medicinal product name	Islatravir
Investigational medicinal product code	
Other name	MK-8591
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

ISL 60 mg tablet, QM, orally for up to 24 months, Part 1 only

Investigational medicinal product name	Placebo to FTC/TAF
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months

Investigational medicinal product name	Placebo to FTC/TDF
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months

Investigational medicinal product name	FTC/TAF
Investigational medicinal product code	
Other name	Descovy Emtricitabine/Tenofovir Alafenamide
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months

<b>Arm title</b>	Parts 1 to 3: FTC/TDF or FTC/TAF
Arm description: Participants received 200/245 mg or 200/300 mg of FTC/TDF combination tablet QD or 200/25 mg of FTC/TAF combination tablet QD at investigator's discretion plus placebo to ISL tablet QM in Part 1. Participants continued to receive open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Arm type	Active comparator
Investigational medicinal product name	FTC/TDF
Investigational medicinal product code	
Other name	Truvada Emtricitabine/Tenofovir Disoproxil Fumarate
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months

Investigational medicinal product name	Placebo to ISL
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Placebo ISL 0 mg tablets QM, orally for up to 24 months.

<b>Number of subjects in period 1</b>	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF	Parts 1 to 3: FTC/TDF or FTC/TAF
Started	328	166
Completed	308	160
Not completed	20	6
Consent withdrawn by subject	12	4
Adverse event, non-fatal	1	-
Lost to follow-up	7	2

**Period 2**

Period 2 title	Parts 2 and 3: Open-Label FTC TDF or TAF
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF
Arm description:	
Participants received 60 mg tablet of ISL once monthly (QM) plus placebo to FTC/TDF tablet once daily (QD) or placebo to FTC/TAF tablet QD in Part 1. Participants then received open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Arm type	Active comparator
Investigational medicinal product name	FTC/TDF
Investigational medicinal product code	
Other name	Truvada Emtricitabine/Tenofovir Disoproxil Fumarate
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months	
Investigational medicinal product name	FTC/TAF
Investigational medicinal product code	
Other name	Descovy Emtricitabine/Tenofovir Alafenamide
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months	

<b>Arm title</b>	Parts 1 to 3: FTC/TDF or FTC/TAF
Arm description:	
Participants received 200/245 mg or 200/300 mg of FTC/TDF combination tablet QD or 200/25 mg of FTC/TAF combination tablet QD at investigator's discretion plus placebo to ISL tablet QM in Part 1. Participants continued to receive open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Arm type	Active comparator
Investigational medicinal product name	FTC/TDF
Investigational medicinal product code	
Other name	Truvada Emtricitabine/Tenofovir Disoproxil Fumarate
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months	
Investigational medicinal product name	FTC/TAF
Investigational medicinal product code	
Other name	Descovy Emtricitabine/Tenofovir Alafenamide
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months	

<b>Number of subjects in period 2<sup>[1]</sup></b>	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF	Parts 1 to 3: FTC/TDF or FTC/TAF
Started	306	154
Completed	0	0
Not completed	306	154
Consent withdrawn by subject	39	23

Physician decision	-	2
Study terminated by Sponsor	227	119
Not reported	6	1
Lost to follow-up	34	9

---

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Period 1 was not completed prior to moving to open-label Parts 2 and 3.

## Baseline characteristics

### Reporting groups

Reporting group title	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF
Reporting group description:	
Participants received 60 mg tablet of ISL once monthly (QM) plus placebo to FTC/TDF tablet once daily (QD) or placebo to FTC/TAF tablet QD in Part 1. Participants then received open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Reporting group title	Parts 1 to 3: FTC/TDF or FTC/TAF
Reporting group description:	
Participants received 200/245 mg or 200/300 mg of FTC/TDF combination tablet QD or 200/25 mg of FTC/TAF combination tablet QD at investigator's discretion plus placebo to ISL tablet QM in Part 1. Participants continued to receive open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	

Reporting group values	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF	Parts 1 to 3: FTC/TDF or FTC/TAF	Total
Number of subjects	328	166	494
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	327	165	492
From 65-84 years	1	1	2
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	29.6	29.5	-
standard deviation	± 9.6	± 9.2	-
Sex: Female, Male Units: Participants			
Female	0	0	0
Male	328	166	494
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	2	0	2
Asian	70	31	101
Native Hawaiian or Other Pacific Islander	2	0	2
Black or African American	83	41	124
White	135	71	206
More than one race	35	20	55
Unknown or Not Reported	1	3	4
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	111	51	162



Not Hispanic or Latino	214	111	325
Unknown or Not Reported	3	4	7

## End points

### End points reporting groups

Reporting group title	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF
Reporting group description: Participants received 60 mg tablet of ISL once monthly (QM) plus placebo to FTC/TDF tablet once daily (QD) or placebo to FTC/TAF tablet QD in Part 1. Participants then received open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Reporting group title	Parts 1 to 3: FTC/TDF or FTC/TAF
Reporting group description: Participants received 200/245 mg or 200/300 mg of FTC/TDF combination tablet QD or 200/25 mg of FTC/TAF combination tablet QD at investigator's discretion plus placebo to ISL tablet QM in Part 1. Participants continued to receive open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Reporting group title	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF
Reporting group description: Participants received 60 mg tablet of ISL once monthly (QM) plus placebo to FTC/TDF tablet once daily (QD) or placebo to FTC/TAF tablet QD in Part 1. Participants then received open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	
Reporting group title	Parts 1 to 3: FTC/TDF or FTC/TAF
Reporting group description: Participants received 200/245 mg or 200/300 mg of FTC/TDF combination tablet QD or 200/25 mg of FTC/TAF combination tablet QD at investigator's discretion plus placebo to ISL tablet QM in Part 1. Participants continued to receive open-label FTC/TDF or FTC/TAF in Parts 2 and 3.	

### Primary: Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment

End point title	Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment <sup>[1]</sup>
End point description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.	
End point type	Primary
End point timeframe: Up to approximately 10.5 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Per protocol, only descriptive statistics are presented.	

End point values	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF	Parts 1 to 3: FTC/TDF or FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	328	166		
Units: Participants	211	128		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Participants Who Discontinued from Blinded Study Treatment Due to an AE

End point title	Number of Participants Who Discontinued from Blinded Study Treatment Due to an AE <sup>[2]</sup>
-----------------	--

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE will be reported for each treatment arm.

End point type	Primary
----------------	---------

End point timeframe:

Up to approximately 9 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, only descriptive statistics are presented.

End point values	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF	Parts 1 to 3: FTC/TDF or FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	328	166		
Units: Participants	1	0		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants with Confirmed HIV-1 infection

End point title	Number of Participants with Confirmed HIV-1 infection
-----------------	---

End point description:

The number of participants with confirmed HIV-1 infections during the blinded treatment period is presented.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 10.5 months

End point values	Part 1: ISL & Parts 2 & 3: FTC/TDF or FTC/TAF	Parts 1 to 3: FTC/TDF or FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	328	166		
Units: Participants	0	0		

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Entire Study: Blinded Treatment (Part 1) + Open-Label Standard-of-Care Treatment (Parts 2 & 3) [Up to approximately 26 months]

Adverse event reporting additional description:

Data are presented separately for Part 1 (randomized blinded treatment) and Parts 2 & 3 (open-label standard-of-care preexposure prophylaxis [PrEP] periods). Open-label PrEP treatment was pooled per protocol as standard-of-care treatment (FTC/TAF as available only for US sites, FTC/TDF as brand [200/300 mg] or generic [200/245 mg]).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

### Reporting groups

Reporting group title	Part 1: ISL
-----------------------	-------------

Reporting group description:

Participants received blinded 60 mg tablet of ISL QM plus placebo to FTC/TDF tablet QD or placebo to FTC/TAF tablet QD in Part 1.

Reporting group title	Part 1: FTC/TDF or FTC/TAF
-----------------------	----------------------------

Reporting group description:

Participants received blinded FTC/TDF (200/245 mg or 200/300 mg) or FTC/TAF (200/25 mg) QD and placebo to ISL QM in Part 1.

Reporting group title	Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1)
-----------------------	---

Reporting group description:

Participants received open-label FTC/TDF or FTC/TAF (based on regional availability) QD in Parts 2 and 3 (after blinded FTC/TDF or FTC/TAF in Part 1).

Reporting group title	Parts 2 & 3: Open-label PrEP (ISL in Part 1)
-----------------------	--

Reporting group description:

Participants received open-label FTC/TDF or FTC/TAF (based on regional availability) QD in Parts 2 and 3 (after blinded ISL in Part 1).

Serious adverse events	Part 1: ISL	Part 1: FTC/TDF or FTC/TAF	Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1)
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 328 (1.83%)	1 / 166 (0.60%)	5 / 154 (3.25%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw fracture			

subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Epilepsy			
subjects affected / exposed	1 / 328 (0.30%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amnesia			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Proctitis			
subjects affected / exposed	1 / 328 (0.30%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Acute psychosis			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance-induced psychotic disorder			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	1 / 154 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations Cellulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 328 (0.00%) 0 / 0 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	0 / 154 (0.00%) 0 / 0 0 / 0
COVID-19 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 328 (0.30%) 0 / 1 0 / 0	1 / 166 (0.60%) 0 / 1 0 / 0	1 / 154 (0.65%) 0 / 1 0 / 0
Appendicitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 328 (0.30%) 0 / 1 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	2 / 154 (1.30%) 0 / 2 0 / 0
Pneumonia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 328 (0.30%) 0 / 1 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	0 / 154 (0.00%) 0 / 0 0 / 0
Peritonsillar abscess subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 328 (0.00%) 0 / 0 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	0 / 154 (0.00%) 0 / 0 0 / 0
Folliculitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 328 (0.30%) 0 / 1 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	0 / 154 (0.00%) 0 / 0 0 / 0
Pyelonephritis acute subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 328 (0.00%) 0 / 0 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	0 / 154 (0.00%) 0 / 0 0 / 0
Dengue fever subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 328 (0.00%) 0 / 0 0 / 0	0 / 166 (0.00%) 0 / 0 0 / 0	0 / 154 (0.00%) 0 / 0 0 / 0
Upper respiratory tract infection			

subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	1 / 154 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 328 (0.00%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 328 (0.30%)	0 / 166 (0.00%)	0 / 154 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Parts 2 & 3: Open-label PrEP (ISL in Part 1)		
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 306 (5.88%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Jaw fracture			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ulna fracture			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Epilepsy			



subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Amnesia			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Proctitis			
subjects affected / exposed	0 / 306 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Acute psychosis			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Substance-induced psychotic disorder			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			
subjects affected / exposed	0 / 306 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
COVID-19			
subjects affected / exposed	8 / 306 (2.61%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		

Appendicitis				
subjects affected / exposed	0 / 306 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 306 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonsillar abscess				
subjects affected / exposed	1 / 306 (0.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Folliculitis				
subjects affected / exposed	0 / 306 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				
subjects affected / exposed	1 / 306 (0.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dengue fever				
subjects affected / exposed	1 / 306 (0.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 306 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Viral infection				
subjects affected / exposed	1 / 306 (0.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				

Hyperglycaemia			
subjects affected / exposed	1 / 306 (0.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Part 1: ISL	Part 1: FTC/TDF or FTC/TAF	Parts 2 & 3: Open-label PrEP (FTC/TDF or FTC/TAF in Part 1)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	120 / 328 (36.59%)	88 / 166 (53.01%)	104 / 154 (67.53%)
Investigations			
CD4 lymphocytes decreased			
subjects affected / exposed	1 / 328 (0.30%)	3 / 166 (1.81%)	6 / 154 (3.90%)
occurrences (all)	1	3	10
Nervous system disorders			
Headache			
subjects affected / exposed	14 / 328 (4.27%)	10 / 166 (6.02%)	9 / 154 (5.84%)
occurrences (all)	14	10	11
Gastrointestinal disorders			
Haemorrhoids			
subjects affected / exposed	3 / 328 (0.91%)	2 / 166 (1.20%)	8 / 154 (5.19%)
occurrences (all)	3	2	9
Diarrhoea			
subjects affected / exposed	19 / 328 (5.79%)	9 / 166 (5.42%)	11 / 154 (7.14%)
occurrences (all)	21	11	11
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	5 / 328 (1.52%)	3 / 166 (1.81%)	5 / 154 (3.25%)
occurrences (all)	5	3	5
Oropharyngeal pain			
subjects affected / exposed	6 / 328 (1.83%)	7 / 166 (4.22%)	9 / 154 (5.84%)
occurrences (all)	6	8	10
Infections and infestations			
Chlamydial infection			

subjects affected / exposed	0 / 328 (0.00%)	2 / 166 (1.20%)	7 / 154 (4.55%)
occurrences (all)	0	2	9
COVID-19			
subjects affected / exposed	35 / 328 (10.67%)	21 / 166 (12.65%)	37 / 154 (24.03%)
occurrences (all)	36	21	41
Oropharyngeal gonococcal infection			
subjects affected / exposed	16 / 328 (4.88%)	11 / 166 (6.63%)	24 / 154 (15.58%)
occurrences (all)	18	11	29
Nasopharyngitis			
subjects affected / exposed	14 / 328 (4.27%)	7 / 166 (4.22%)	11 / 154 (7.14%)
occurrences (all)	14	8	12
Latent syphilis			
subjects affected / exposed	2 / 328 (0.61%)	0 / 166 (0.00%)	3 / 154 (1.95%)
occurrences (all)	2	0	3
Influenza			
subjects affected / exposed	4 / 328 (1.22%)	6 / 166 (3.61%)	14 / 154 (9.09%)
occurrences (all)	4	7	15
Pharyngeal chlamydia infection			
subjects affected / exposed	2 / 328 (0.61%)	1 / 166 (0.60%)	2 / 154 (1.30%)
occurrences (all)	2	1	2
Syphilis			
subjects affected / exposed	10 / 328 (3.05%)	7 / 166 (4.22%)	15 / 154 (9.74%)
occurrences (all)	10	7	15
Proctitis gonococcal			
subjects affected / exposed	13 / 328 (3.96%)	15 / 166 (9.04%)	30 / 154 (19.48%)
occurrences (all)	14	16	41
Proctitis chlamydial			
subjects affected / exposed	20 / 328 (6.10%)	14 / 166 (8.43%)	27 / 154 (17.53%)
occurrences (all)	25	14	37
Upper respiratory tract infection			
subjects affected / exposed	10 / 328 (3.05%)	8 / 166 (4.82%)	17 / 154 (11.04%)
occurrences (all)	10	8	20

<b>Non-serious adverse events</b>	Parts 2 & 3: Open-label PrEP (ISL in Part 1)		
Total subjects affected by non-serious adverse events			

subjects affected / exposed	230 / 306 (75.16%)		
Investigations			
CD4 lymphocytes decreased			
subjects affected / exposed	24 / 306 (7.84%)		
occurrences (all)	29		
Nervous system disorders			
Headache			
subjects affected / exposed	18 / 306 (5.88%)		
occurrences (all)	23		
Gastrointestinal disorders			
Haemorrhoids			
subjects affected / exposed	12 / 306 (3.92%)		
occurrences (all)	12		
Diarrhoea			
subjects affected / exposed	14 / 306 (4.58%)		
occurrences (all)	14		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	16 / 306 (5.23%)		
occurrences (all)	17		
Oropharyngeal pain			
subjects affected / exposed	13 / 306 (4.25%)		
occurrences (all)	15		
Infections and infestations			
Chlamydial infection			
subjects affected / exposed	17 / 306 (5.56%)		
occurrences (all)	19		
COVID-19			
subjects affected / exposed	69 / 306 (22.55%)		
occurrences (all)	79		
Oropharyngeal gonococcal infection			
subjects affected / exposed	41 / 306 (13.40%)		
occurrences (all)	55		
Nasopharyngitis			
subjects affected / exposed	27 / 306 (8.82%)		
occurrences (all)	33		
Latent syphilis			

subjects affected / exposed	18 / 306 (5.88%)		
occurrences (all)	22		
Influenza			
subjects affected / exposed	14 / 306 (4.58%)		
occurrences (all)	19		
Pharyngeal chlamydia infection			
subjects affected / exposed	18 / 306 (5.88%)		
occurrences (all)	18		
Syphilis			
subjects affected / exposed	19 / 306 (6.21%)		
occurrences (all)	20		
Proctitis gonococcal			
subjects affected / exposed	51 / 306 (16.67%)		
occurrences (all)	63		
Proctitis chlamydial			
subjects affected / exposed	65 / 306 (21.24%)		
occurrences (all)	81		
Upper respiratory tract infection			
subjects affected / exposed	31 / 306 (10.13%)		
occurrences (all)	32		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 June 2021	AM1: The purpose of this amendment was to update the statistical methods for primary and secondary objectives.
06 December 2021	AM2: The purpose of this amendment was to increase frequency of monitoring of lymphocytes and to add C4+ T-cell monitoring.
24 February 2022	AM3: The purpose of this amendment was to halt dosing of blinded study intervention and to give participants the option to receive daily FTC/TDF or FTC/TAF.
03 August 2022	AM4: The purpose of this amendment was to add Part 3 to unblind each participant's Part 1 study intervention and monitor safety.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
10 December 2021	Dosing of blinded study intervention was halted on 10-Dec-2021 due to findings of decreased lymphocyte and CD4+ T-cell counts.	-

Notes:

### Limitations and caveats

None reported